resTORbio, Inc. (NASDAQ:TORC) Director Orbimed Advisors Llc purchased 533,333 shares of the stock in a transaction dated Tuesday, January 30th. The stock was acquired at an average cost of $15.00 per share, with a total value of $7,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
resTORbio, Inc. (NASDAQ:TORC) opened at $18.09 on Thursday. resTORbio, Inc. has a 52 week low of $15.18 and a 52 week high of $20.50.
TRADEMARK VIOLATION WARNING: “Insider Buying: resTORbio, Inc. (NASDAQ:TORC) Director Buys 533,333 Shares of Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/15/restorbio-inc-torc-director-orbimed-advisors-llc-buys-533333-shares-of-stock.html.
resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.